3-aminobenzamide has been researched along with Myocardial Infarction in 12 studies
Myocardial Infarction: NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).
| Excerpt | Relevance | Reference |
|---|---|---|
| " The apparent median terminal half-life (t(1/2)) of INO-1001 was 7." | 2.74 | A randomized, placebo-controlled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary perc ( Baran, K; Brickman, CM; Dauerman, H; Grip, L; Krakover, R; Kumar, S; McCabe, CH; Morrow, DA; Murphy, SA; Salzman, AL; Slomowitz, N, 2009) |
| " However, at the dosage tested in the present study, the improvement is in general moderate." | 1.43 | Effects of 3-aminobenzamide on ventricular function in infarct heart assessed by quantitative tissue velocity imaging. ( Hu, B; Pan, XQ; Shen, E; Wang, M; Zhang, YL, 2016) |
| "Pharmacological protection from myocardial reperfusion injury, despite plenty of approaches, has still not been realized in humans." | 1.36 | Therapeutic injection of PARP inhibitor INO-1001 preserves cardiac function in porcine myocardial ischemia and reperfusion without reducing infarct size. ( Barthuber, C; Bergt, S; Bohnenberg, K; Mersmann, J; Nöldge-Schomburg, GE; Roesner, JP; Szabo, C; Zacharowski, K, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 6 (50.00) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eltze, T | 1 |
| Boer, R | 1 |
| Wagner, T | 1 |
| Weinbrenner, S | 1 |
| McDonald, MC | 1 |
| Thiemermann, C | 4 |
| Bürkle, A | 1 |
| Klein, T | 1 |
| Nishizawa, K | 1 |
| Yanagida, S | 1 |
| Yamagishi, T | 1 |
| Takayama, E | 1 |
| Bessho, M | 1 |
| Kusuhara, M | 1 |
| Adachi, T | 1 |
| Ohsuzu, F | 1 |
| Wang, M | 1 |
| Hu, B | 1 |
| Zhang, YL | 1 |
| Shen, E | 1 |
| Pan, XQ | 1 |
| Zhao, YJ | 1 |
| Wang, JH | 1 |
| Fu, B | 1 |
| Ma, MX | 1 |
| Li, BX | 1 |
| Huang, Q | 1 |
| Yang, BF | 1 |
| Bowes, J | 2 |
| Myint, FP | 1 |
| Vane, JR | 1 |
| Ruetten, H | 1 |
| Martorana, PA | 1 |
| Stockhausen, H | 1 |
| Liaudet, L | 1 |
| Timashpolsky, L | 1 |
| Virág, L | 1 |
| Cziráki, A | 1 |
| Szabó, C | 4 |
| Morrow, DA | 1 |
| Brickman, CM | 1 |
| Murphy, SA | 1 |
| Baran, K | 1 |
| Krakover, R | 1 |
| Dauerman, H | 1 |
| Kumar, S | 1 |
| Slomowitz, N | 1 |
| Grip, L | 1 |
| McCabe, CH | 1 |
| Salzman, AL | 1 |
| Rehberg, S | 1 |
| Traber, DL | 1 |
| Roesner, JP | 1 |
| Mersmann, J | 1 |
| Bergt, S | 1 |
| Bohnenberg, K | 1 |
| Barthuber, C | 1 |
| Nöldge-Schomburg, GE | 1 |
| Zacharowski, K | 1 |
| Murthy, KG | 1 |
| Xiao, CY | 2 |
| Mabley, JG | 1 |
| Chen, M | 2 |
| Zsengellér, Z | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Randomized, Placebo-Controlled, Single-Blind, Multi-Center Dose-Escalation Study to Evaluate Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of a Single Intravenous Administration of INO-1001 in Subjects With ST-Elevation Myocardia[NCT00271765] | Phase 2 | 40 participants | Interventional | 2004-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for 3-aminobenzamide and Myocardial Infarction
| Article | Year |
|---|---|
A randomized, placebo-controlled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary perc
Topics: Angioplasty, Balloon, Coronary; Dose-Response Relationship, Drug; Electrocardiography; Female; Half- | 2009 |
11 other studies available for 3-aminobenzamide and Myocardial Infarction
| Article | Year |
|---|---|
Imidazoquinolinone, imidazopyridine, and isoquinolindione derivatives as novel and potent inhibitors of the poly(ADP-ribose) polymerase (PARP): a comparison with standard PARP inhibitors.
Topics: Animals; Cell Line; Cell Line, Tumor; Fibroblasts; Humans; Imidazoles; Isoquinolines; Kinetics; Male | 2008 |
Continuous inhibition of poly(ADP-ribose) polymerase does not reduce reperfusion injury in isolated rat heart.
Topics: Animals; Apoptosis; Benzamides; Blotting, Western; Cardiotonic Agents; Enzyme Inhibitors; In Vitro T | 2013 |
Effects of 3-aminobenzamide on ventricular function in infarct heart assessed by quantitative tissue velocity imaging.
Topics: Animals; Benzamides; Disease Models, Animal; Echocardiography; Female; Linear Models; Myocardial Inf | 2016 |
Effects of 3-aminobenzamide on expressions of poly (ADP ribose) polymerase and apoptosis inducing factor in cardiomyocytes of rats with acute myocardial infarction.
Topics: Animals; Apoptosis Inducing Factor; Benzamides; Blotting, Western; Enzyme Inhibitors; Immunohistoche | 2009 |
Inhibition of the activity of poly(ADP ribose) synthetase reduces ischemia-reperfusion injury in the heart and skeletal muscle.
Topics: Animals; Benzamides; Enzyme Inhibitors; Male; Muscle, Skeletal; Myocardial Infarction; Myocardium; N | 1997 |
Reduction of myocardial reperfusion injury by an inhibitor of poly (ADP-ribose) synthetase in the pig.
Topics: Animals; Benzamides; Blood Pressure; Cell Death; Cells, Cultured; Enzyme Inhibitors; Eukaryotic Cell | 1998 |
Suppression of poly (ADP-ribose) polymerase activation by 3-aminobenzamide in a rat model of myocardial infarction: long-term morphological and functional consequences.
Topics: Animals; Benzamides; Creatine Kinase; Disease Models, Animal; Enzyme Activation; Heart; Hemodynamics | 2001 |
Increased inotropism following PARP inhibition in the setting of myocardial reperfusion injury: another piece in the jigsaw?
Topics: Animals; Cardiotonic Agents; Indoles; Myocardial Infarction; Myocardial Reperfusion Injury; Poly(ADP | 2010 |
Therapeutic injection of PARP inhibitor INO-1001 preserves cardiac function in porcine myocardial ischemia and reperfusion without reducing infarct size.
Topics: Animals; Cardiotonic Agents; Hemodynamics; Indoles; Ischemic Preconditioning, Myocardial; Male; Myoc | 2010 |
Activation of poly(ADP-ribose) polymerase in circulating leukocytes during myocardial infarction.
Topics: Animals; Blotting, Western; Cell Line, Tumor; DNA; DNA Damage; Enzyme Activation; Enzyme Inhibitors; | 2004 |
Poly(ADP-ribose) polymerase contributes to the development of myocardial infarction in diabetic rats and regulates the nuclear translocation of apoptosis-inducing factor.
Topics: Animals; Apoptosis Inducing Factor; Cell Nucleus; Diabetes Mellitus, Experimental; Enzyme Activation | 2004 |